17 results on '"Miele, Luca"'
Search Results
2. Non‐alcoholic fatty liver disease and the risk of fibrosis in Italian primary care services: GPS‐NAFLD Study.
- Author
-
Miele, Luca, Grattagliano, Ignazio, Lapi, Francesco, Dajko, Marianxhela, De Magistris, Antonio, Liguori, Antonio, De Matthaeis, Nicoletta, Rossi, Alessandro, Gasbarrini, Antonio, Cricelli, Claudio, and Grieco, Antonio
- Subjects
- *
NON-alcoholic fatty liver disease , *HEPATIC fibrosis , *PRIMARY care , *FATTY liver , *FIBROSIS - Abstract
Background and aims: The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing globally. This study aimed to determine the prevalence of NAFLD and the probability of liver fibrosis in Italian primary care services. Methods: We carried out a population‐based and nested case–control study including all individuals aged 18 years and above registered at Italian primary care services. Data were collected from the general practitioners' network from 2010 to 2017. NAFLD cases were identified via the ICD‐9‐CM and Hepatic Steatosis Index score > 36 and were matched each up to 10 controls. Other causes of liver diseases were excluded. The risk of fibrosis was assessed using the FIB‐4 and NAFLD fibrosis scores (NFS). Results: NAFLD was present in 9% of the primary care population with high regional variability. Among NAFLD subjects: 25% had diabetes, 10% had chronic kidney disease, 11% had cardiovascular disease and 28% were obese. Furthermore, 30% had at least two comorbidities and 13% had cirrhosis. Once cirrhosis was excluded, the risk of any degree of fibrosis was 13.8% with NFS and 20.5% with FIB‐4 in subjects <65 years. Conclusions: Even if there is an identification gap in primary care, recorded cases with NAFLD have a high frequency of associated comorbidities. Despite regional variability, a close relation between cirrhosis and NAFLD exists (OR: 3.48, 95% CI: 3.23–3.76). Therefore, the use of non‐invasive tests should be promoted in primary care as a useful tool for the early identification of fibrosis risk, independently of evidence of steatosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. COVID‐19, adaptative immune response and metabolic‐associated liver disease.
- Author
-
Miele, Luca, Napodano, Cecilia, Cesario, Alfredo, De Magistris, Antonio, Pocino, Krizia, Basile, Umberto, Rapaccini, Gian L., Gasbarrini, Antonio, and Grieco, Antonio
- Subjects
- *
FATTY liver , *METABOLIC disorders , *COVID-19 , *LIVER diseases , *NON-alcoholic fatty liver disease , *IMMUNE response , *GUT microbiome - Abstract
Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID‐19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low‐grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non‐alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID‐19 can have a worse outcome of COVID‐19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID‐19 complexity and to improve knowledge on its pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility.
- Author
-
Pugliese, Nicola, Polverini, Davide, Lombardi, Rosa, Pennisi, Grazia, Ravaioli, Federico, Armandi, Angelo, Buzzetti, Elena, Dalbeni, Andrea, Liguori, Antonio, Mantovani, Alessandro, Villani, Rosanna, Gardini, Ivan, Hassan, Cesare, Valenti, Luca, Miele, Luca, Petta, Salvatore, Sebastiani, Giada, and Aghemo, Alessio
- Abstract
Background: Artificial intelligence (AI)-based chatbots have shown promise in providing counseling to patients with metabolic dysfunction-associated steatotic liver disease (MASLD). While ChatGPT3.5 has demonstrated the ability to comprehensively answer MASLD-related questions in English, its accuracy remains suboptimal. Whether language influences these results is unclear. This study aims to assess ChatGPT's performance as a counseling tool for Italian MASLD patients. Methods: Thirteen Italian experts rated the accuracy, completeness and comprehensibility of ChatGPT3.5 in answering 15 MASLD-related questions in Italian using a six-point accuracy, three-point completeness and three-point comprehensibility Likert's scale. Results: Mean scores for accuracy, completeness and comprehensibility were 4.57 ± 0.42, 2.14 ± 0.31 and 2.91 ± 0.07, respectively. The physical activity domain achieved the highest mean scores for accuracy and completeness, whereas the specialist referral domain achieved the lowest. Overall, Fleiss's coefficient of concordance for accuracy, completeness and comprehensibility across all 15 questions was 0.016, 0.075 and −0.010, respectively. Age and academic role of the evaluators did not influence the scores. The results were not significantly different from our previous study focusing on English. Conclusion: Language does not appear to affect ChatGPT's ability to provide comprehensible and complete counseling to MASLD patients, but accuracy remains suboptimal in certain domains. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
- Author
-
McTeer, Matthew, Applegate, Douglas, Mesenbrink, Peter, Ratziu, Vlad, Schattenberg, Jörn M., Bugianesi, Elisabetta, Geier, Andreas, Romero Gomez, Manuel, Dufour, Jean-Francois, Ekstedt, Mattias, Francque, Sven, Yki-Jarvinen, Hannele, Allison, Michael, Valenti, Luca, Miele, Luca, Pavlides, Michael, Cobbold, Jeremy, Papatheodoridis, Georgios, Holleboom, Adriaan G., and Tiniakos, Dina
- Subjects
- *
SUPERVISED learning , *MACHINE learning , *METABOLIC disorders , *LIVER diseases , *PREDICTION models - Abstract
Aims: Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are ordinarily determined by resource-intensive and invasive biopsies. We aim to show that routine clinical tests offer sufficient information to predict these endpoints. Methods: Using the LITMUS Metacohort derived from the European NAFLD Registry, the largest MASLD dataset in Europe, we create three combinations of features which vary in degree of procurement including a 19-variable feature set that are attained through a routine clinical appointment or blood test. This data was used to train predictive models using supervised machine learning (ML) algorithm XGBoost, alongside missing imputation technique MICE and class balancing algorithm SMOTE. Shapley Additive exPlanations (SHAP) were added to determine relative importance for each clinical variable. Results: Analysing nine biopsy-derived MASLD outcomes of cohort size ranging between 5385 and 6673 subjects, we were able to predict individuals at training set AUCs ranging from 0.719-0.994, including classifying individuals who are At-Risk MASH at an AUC = 0.899. Using two further feature combinations of 26-variables and 35-variables, which included composite scores known to be good indicators for MASLD endpoints and advanced specialist tests, we found predictive performance did not sufficiently improve. We are also able to present local and global explanations for each ML model, offering clinicians interpretability without the expense of worsening predictive performance. Conclusions: This study developed a series of ML models of accuracy ranging from 71.9—99.4% using only easily extractable and readily available information in predicting MASLD outcomes which are usually determined through highly invasive means. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.
- Author
-
Marrone, Giuseppe, Leone, Maria Sandrina, Biolato, Marco, Liguori, Antonio, Bianco, Giuseppe, Spoletini, Gabriele, Gasbarrini, Antonio, Miele, Luca, and Pompili, Maurizio
- Subjects
- *
PILOT projects , *LIVER tumors , *CANCER relapse , *MTOR inhibitors , *UNCERTAINTY , *IMMUNOSUPPRESSION , *POSTOPERATIVE period , *LIVER transplantation , *HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) results in a relevant worsening of the prognosis of transplanted subjects. Pre-transplant HCC characteristics are the main determinants of the risk of recurrence and various tools exist to estimate recurrence risk. Once recurrence has occurred, the pattern of recurrence greatly influences whether the patient is a candidate for curative treatment and consequently significantly impacts prognosis. We reviewed different predictive models of post-transplant recurrence, the role of immunosuppression, and the efficacy and feasibility of various therapeutic approaches. Hepatocellular carcinoma (HCC) is a growing indication for liver transplantation (LT). Careful candidate selection is a prerequisite to keep post-LT recurrence rates within acceptable percentages. In the pre-LT period, various types of locoregional treatments and/or systemic therapies can be used for bridging or downstaging purposes. In this context, one of the factors limiting the possibility of treatment is the degree of functional liver impairment. In the LT subject, no widely accepted indications are available to guide treatment of disease recurrence and heterogeneity exists between transplant centers. Improved liver function post LT makes multiple therapeutic strategies theoretically feasible, but patient management is complicated by the need to adjust immunosuppressive therapy and to assess potential toxicities and drug–drug interactions. Finally, there is controversy and uncertainty about the use of recently introduced immunotherapeutic drugs, mainly due to the risk of organ rejection. In this paper, we will review the most recent available literature on the management of post-transplant HCC recurrence, discussing evidence and controversies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. The Liver in Heart Failure: From Biomarkers to Clinical Risk.
- Author
-
Aspromonte, Nadia, Fumarulo, Isabella, Petrucci, Lucrezia, Biferali, Bianca, Liguori, Antonio, Gasbarrini, Antonio, Massetti, Massimo, and Miele, Luca
- Subjects
- *
LIVER failure , *HEART failure , *HEART diseases , *HEART , *BIOMARKERS , *DISEASE management - Abstract
Heart failure (HF) is a clinical syndrome due to heart dysfunction, but in which other organs are also involved, resulting in a complex multisystemic disease, burdened with high mortality and morbidity. This article focuses on the mutual relationship between the heart and liver in HF patients. Any cause of right heart failure can cause hepatic congestion, with important prognostic significance. We have analyzed the pathophysiology underlying this double interaction. Moreover, we have explored several biomarkers and non-invasive tests (i.e., liver stiffness measurement, LSM) potentially able to provide important support in the management of this complex disease. Cardiac biomarkers have been studied extensively in cardiology as a non-invasive diagnostic and monitoring tool for HF. However, their usefulness in assessing liver congestion in HF patients is still being researched. On the other hand, several prognostic scores based on liver biomarkers in patients with HF have been proposed in recent years, recognizing the important burden that liver involvement has in HF. We also discuss the usefulness of a liver stiffness measurement (LSM), which has been recently proposed as a reliable and non-invasive method for assessing liver congestion in HF patients, with therapeutic and prognostic intentions. Lastly, the relationship between LSM and biomarkers of liver congestion is not clearly defined; more research is necessary to establish the clinical value of biomarkers in assessing liver congestion in HF patients and their relationship with LSM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Urinary lithogenic profile of patients with non-alcoholic fatty liver disease.
- Author
-
Bargagli, Matteo, Liguori, Antonio, Napodano, Cecilia, Baroni, Silvia, Tomasello, Lidia, Pizzolante, Fabrizio, Matthaeis, Nicoletta De, Ninno, Grazia De, Grieco, Antonio, Gasbarrini, Antonio, Gambaro, Giovanni, Ferraro, Pietro Manuel, and Miele, Luca
- Subjects
- *
FATTY liver , *NON-alcoholic fatty liver disease , *KIDNEY stones - Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, ranging from pure steatosis to non-alcoholic steatohepatitis and ultimately to liver cirrhosis. In our study, adult NAFLD patients did not have different oxalate excretion values [ -0.26 (95% CI -1.59-1.08), I P i =.681] and only altered urinary ammonium and magnesium excretions were found as proposed risk factors for nephrolithiasis (Fig. Our findings indicate the need for further prospective studies to compare the characteristics of NAFLD patients with and without nephrolithiasis and its incidence at different degrees of NAFLD severity to expand on the observations reported here. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
9. TOP-144-YI Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease.
- Author
-
Mureddu, Matteo, Pelusi, Serena, Ronzoni, Luisa, Malvestiti, Francesco, Moretti, Vittoria, Eigadeh, Hadi, Soardo, Giorgio, Federico, Alessandro, Russo, Francesco Paolo, Fracanzani, Anna Ludovica, Vespasiani-Gentilucci, Umberto, Miele, Luca, Bugianesi, Elisabetta, D'Ambrosio, Roberta, Petta, Salvatore, Fraquelli, Mirella, Prati, Daniele, and Valenti, Luca
- Published
- 2024
- Full Text
- View/download PDF
10. Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
- Author
-
Baselli, Guido A., Jamialahmadi, Oveis, Pelusi, Serena, Ciociola, Ester, Malvestiti, Francesco, Saracino, Marco, Santoro, Luigi, Cherubini, Alessandro, Dongiovanni, Paola, Maggioni, Marco, Bianco, Cristiana, Tavaglione, Federica, Cespiati, Annalisa, Mancina, Rosellina M., D'Ambrosio, Roberta, Vaira, Valentina, Petta, Salvatore, Miele, Luca, Vespasiani-Gentilucci, Umberto, and Federico, Alessandro
- Subjects
- *
GENETIC variation , *NON-alcoholic fatty liver disease , *FATTY liver , *HEPATIC fibrosis , *IMMOBILIZED proteins , *LIVER diseases - Abstract
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci that contribute to severe NAFLD by examining rare variants. We performed whole-exome sequencing in individuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n = 301) and examined the enrichment of likely pathogenic rare variants vs. the general population. This was followed by validation at the gene level. In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; odds ratio [OR] 5.26, 95% CI 2.1-12.6; p = 0.003) of autophagy-related 7 (ATG7) , which we characterized as a loss-of-function, vs. the general population, and an enrichment in rare variants affecting the catalytic domain (OR 13.9; 95% CI 1.9-612; p = 0.002). In the UK Biobank cohort, loss-of-function ATG7 variants increased the risk of cirrhosis and hepatocellular carcinoma (OR 3.30; 95% CI 1.1-7.5 and OR 12.30, 95% CI 2.6-36, respectively; p < 0.001 for both). The low-frequency loss-of-function p.V471A variant (rs36117895 T>C) was also associated with severe NAFLD in the clinical cohort (OR 1.7; 95% CI 1.2-2.5; p = 0.003), predisposed to hepatocellular ballooning (p = 0.007) evolving to fibrosis in the Liver biopsy cohort (n = 2,268), and was associated with liver injury in the UK Biobank (aspartate aminotransferase levels, p < 0.001), with a larger effect in severely obese individuals in whom it was linked to hepatocellular carcinoma (p = 0.009). ATG7 protein localized to periportal hepatocytes, particularly in the presence of ballooning. In the Liver Transcriptomic cohort (n = 125), ATG7 expression correlated with suppression of the TNFα pathway, which was conversely upregulated in p.V471A carriers. We identified rare and low-frequency ATG7 loss-of-function variants that promote NAFLD progression by impairing autophagy and facilitating ballooning and inflammation. We found that rare mutations in a gene called autophagy-related 7 (ATG7) increase the risk of developing severe liver disease in individuals with dysmetabolism. These mutations cause an alteration in protein function and impairment of self-renewal of cellular content, leading to liver damage and inflammation. [Display omitted] • NAFLD is the leading cause of liver disorders and has a strong heritable component. • Rare loss-of-function ATG7 gene mutations increase the risk of severe liver disease in patients with NAFLD. • ATG7 mutations cause altered protein function and impairment of autophagy, leading to hepatocellular ballooning and inflammation. • The most frequent variant is responsible for a meaningful fraction of predisposition to ballooning and hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. WED-215 HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning.
- Author
-
Angelini, Giulia, Russo, Sara, Lembo, Erminia, Verrastro, Ornella, Guidone, Caterina, Liguori, Antonio, Harrison, Stephen A., Trylesinski, Aldo, Miele, Luca, and Mingrone, Geltrude
- Published
- 2024
- Full Text
- View/download PDF
12. FRI-290 Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness.
- Author
-
Pugliese, Nicola, Polverini, Davide, Lombardi, Rosa, Pennisi, Grazia, Ravaioli, Federico, Armandi, Angelo, Buzzetti, Elena, Dalbeni, Andrea, Liguori, Antonio, Mantovani, Alessandro, Villani, Rosanna, Hassan, Cesare, Valenti, Luca, Miele, Luca, Petta, Salvatore, Sebastiani, Giada, and Aghemo, Alessio
- Published
- 2024
- Full Text
- View/download PDF
13. TOP-301 Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease.
- Author
-
Pelusi, Serena, Marchetti, Alfredo, Malvestiti, Francesco, Ricchiuti, Antony, Ronzoni, Luisa, Lionetti, Marta, Moretti, Vittoria, Bugianesi, Elisabetta, Miele, Luca, Gentilucci, Umberto Vespasiani, Dongiovanni, Paola, Federico, Alessandro, Soardo, Giorgio, D'Ambrosio, Roberta, Reeves, Helen Louise, La Mura, Vincenzo, Prati, Daniele, Bolli, Niccolò, and Valenti, Luca
- Published
- 2024
- Full Text
- View/download PDF
14. Machine Learning-Assisted FTIR Analysis of Circulating Extracellular Vesicles for Cancer Liquid Biopsy.
- Author
-
Di Santo, Riccardo, Vaccaro, Maria, Romanò, Sabrina, Di Giacinto, Flavio, Papi, Massimiliano, Rapaccini, Gian Ludovico, De Spirito, Marco, Miele, Luca, Basile, Umberto, and Ciasca, Gabriele
- Subjects
- *
ALPHA fetoproteins , *EXTRACELLULAR vesicles , *FISHER discriminant analysis , *FOURIER transform infrared spectroscopy , *TUMOR markers , *VITAMIN K , *HYPERSPECTRAL imaging systems - Abstract
Extracellular vesicles (EVs) are abundantly released into the systemic circulation, where they show remarkable stability and harbor molecular constituents that provide biochemical information about their cells of origin. Due to this characteristic, EVs are attracting increasing attention as a source of circulating biomarkers for cancer liquid biopsy and personalized medicine. Despite this potential, none of the discovered biomarkers has entered the clinical practice so far, and novel approaches for the label-free characterization of EVs are highly demanded. In this regard, Fourier Transform Infrared Spectroscopy (FTIR) has great potential as it provides a quick, reproducible, and informative biomolecular fingerprint of EVs. In this pilot study, we investigated, for the first time in the literature, the capability of FTIR spectroscopy to distinguish between EVs extracted from sera of cancer patients and controls based on their mid-IR spectral response. For this purpose, EV-enriched suspensions were obtained from the serum of patients diagnosed with Hepatocellular Carcinoma (HCC) of nonviral origin and noncancer subjects. Our data point out the presence of statistically significant differences in the integrated intensities of major mid-IR absorption bands, including the carbohydrate and nucleic acids band, the protein amide I and II bands, and the lipid CH stretching band. Additionally, we used Principal Component Analysis combined with Linear Discriminant Analysis (PCA-LDA) for the automated classification of spectral data according to the shape of specific mid-IR spectral signatures. The diagnostic performances of the proposed spectral biomarkers, alone and combined, were evaluated using multivariate logistic regression followed by a Receiving Operator Curve analysis, obtaining large Areas Under the Curve (AUC = 0.91, 95% CI 0.81–1.0). Very interestingly, our analyses suggest that the discussed spectral biomarkers can outperform the classification ability of two widely used circulating HCC markers measured on the same groups of subjects, namely alpha-fetoprotein (AFP), and protein induced by the absence of vitamin K or antagonist-II (PIVKA-II). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression.
- Author
-
Pocino, Krizia, Napodano, Cecilia, Gragnani, Laura, Ciasca, Gabriele, Colantuono, Stefania, Marri, Silvia, Vantaggio, Lorenzo, Gulli, Francesca, Lorini, Serena, Barini, Antonella, Stefanile, Annunziata, Miele, Luca, Casato, Milvia, Zignego, Anna Linda, Rapaccini, Gian Ludovico, Marino, Mariapaola, Visentini, Marcella, and Basile, Umberto
- Subjects
- *
BIOMARKERS , *HEPATITIS B , *DISEASE progression , *IMMUNOGLOBULINS , *CONFIDENCE intervals , *HEMOSTASIS , *RETROSPECTIVE studies , *MANN Whitney U Test , *DESCRIPTIVE statistics , *VASCULAR diseases , *DATA analysis software , *LOGISTIC regression analysis , *DISEASE complications - Abstract
Objectives The biomarkers of an immunological dysregulation due to a chronic HBV infection are indeed understudied. If untreated, this condition may evolve into liver impairment co-occurring with extrahepatic involvements. Here, we aim to identify a new panel of biomarkers [including immunoglobulin G (IgG) subclasses, RF, and Free Light Chains (FLCs)] that may be useful and reliable for clinical evaluation of HBV-related cryoglobulinemia. Methods We retrospectively analysed clinical data from 44 HBV-positive patients. The patients were stratified (according to the presence/absence of mixed cryoglobulinemia) into two groups: 22 with cryoglobulins (CGs) and 22 without CGs. Samples from 20 healthy blood donors (HDs) were used as negative controls. Serum samples were tested for IgG subclasses, RF (-IgM, -IgG, and -IgA type), and FLCs. Results We detected a strikingly different distribution of serum IgG subclasses between HDs and HBV-positive patients, together with different RF isotypes; in addition, FLCs were significantly increased in HBV-positive patients compared with HDs, while no significant difference was shown between HBV-positive patients with/without mixed cryoglobulinemia. Conclusion The immune-inflammatory response triggered by HBV may be monitored by a peculiar profile of biomarkers. Our results open a new perspective in the precision medicine era; in these challenging times, they could also be employed to monitor the clinical course of those COVID-19 patients who are at high risk of HBV reactivation due to liver impairment and/or immunosuppressive therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. A Comparative Study of Serum Angiogenic Biomarkers in Cirrhosis and Hepatocellular Carcinoma.
- Author
-
Pocino, Krizia, Napodano, Cecilia, Marino, Mariapaola, Di Santo, Riccardo, Miele, Luca, De Matthaeis, Nicoletta, Gulli, Francesca, Saporito, Raffaele, Rapaccini, Gian Ludovico, Ciasca, Gabriele, and Basile, Umberto
- Subjects
- *
BIOMARKERS , *DISEASE progression , *CIRRHOSIS of the liver , *COMPARATIVE studies , *ENZYME-linked immunosorbent assay , *HEPATOCELLULAR carcinoma - Abstract
Simple Summary: The progression of liver disease is accompanied by pathological angiogenesis, a prerequisite for the development of HCC. In this paper, we analyzed the clinical significance of serum angiogenic markers VEGF, Ang-1, Ang-2, angiopoietin receptor Tie1/2, HGF, and PECAM-1 in 62 patients with liver disease, out of which 33 were diagnosed with HCC and 29 with liver cirrhosis without signs of neoplasia. Biomarkers levels were investigated as a function of "Model for End-Stage Liver Disease" (MELD) score and Fibrosis Index (FI). HCC patients showed higher HGF levels than ones with cirrhosis, while high Ang-1 levels appeared to have a protective role in HCC as well as prognostic significance; we also found a strong correlation between HGF levels, Ang-2, and VEGF levels, further supporting their role in tumor angiogenesis. Due to the complexity of angiogenesis and the small size of the study group, further investigations are widely desired especially in the era of immunotherapy and HCC-targeted anti-angiogenic drugs. Background: Hepatocellular carcinoma (HCC) is a global health problem associated with chronic liver disease. Its pathogenesis varies according to the underlying etiological factors, although in most cases it develops from liver cirrhosis. The disease progression is accompanied by pathological angiogenesis, which is a prerequisite that favors the development of HCC. Aims: This study aims at contributing to our understanding of the role of angiogenic factors in the progression of liver disease. For this purpose, we evaluate the clinical significance of serum angiogenic markers (VEGF, Ang-1, Ang-2, the angiopoietin receptor Tie1/2, HGF, and PECAM-1) first in cirrhotic and HCC patients separately, and then comparing cirrhotic patients with and without HCC. Materials and Methods: We enrolled 62 patients, out of whom 33 were diagnosed with HCC and 29 with liver cirrhosis without signs of neoplasia. Patients underwent venous blood sampling before and after receiving treatments for the diagnosed disease. Serum markers were evaluated using ELISA assays for Tie1 and the Bio-Plex Multiplex system for the remaining ones. Biomarker levels were investigated as a function of clinical scores for disease staging (MELD and Fibrosis Index, FI). Results: In cirrhotic patients, Ang-1 and Ang-2 correlate with MELD (ρAng-1 = −0.73, p = 2E−5) and FI (ρAng-1 = −0.52, p = 7E−3, ρAng-2 = 0.53, p = 3E−3). A reduction of Ang-2 levels (p = 0.047) and of the Ang-2/Ang-1 ratio (p = 0.031) is observed in cirrhotic patients diagnosed with viral hepatitis after antiviral treatments. In HCC patients, Ang-1 negatively correlates with FI (ρ = −0.63, p = 1E−4), and PECAM-1 positively correlates with MELD (ρ = 0.44, p = 0.01). A significant Ang-1 reduction was observed in deceased patients during the study compared to ones who survived (p = 0.01). In HCC patients, VEGF levels were increased after tumor treatment (p = 0.037). Notably, HGF levels in cirrhotic patients with HCC are significantly raised (p = 0.017) compared to that in those without HCC. Conclusions: Our results suggest that serum angiogenic markers, with emphasis on Ang-1/2, can contribute to the development of quantitative tools for liver disease staging and therapy monitoring. The comparison between cirrhotic patients with and without HCC suggests that HGF levels are potentially useful for monitoring the insurgence of HCC after a cirrhosis diagnosis. High Ang-1 levels in HCC patients appear to have a protective role as well as prognostic significance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.
- Author
-
Biolato, Marco, Galasso, Tiziano, Marrone, Giuseppe, Miele, Luca, and Grieco, Antonio
- Subjects
- *
ALPHA fetoproteins , *PATIENT selection , *RADIOEMBOLIZATION , *CANCER chemotherapy , *METASTASIS , *EARLY detection of cancer , *CHEMOEMBOLIZATION , *CANCER patients , *ELIGIBILITY (Social aspects) , *LIVER transplantation , *TUMOR markers , *HEPATOCELLULAR carcinoma , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Simple Summary: Currently, most transplant centres worldwide accept patients with hepatocellular carcinoma who underwent successful downstaging. Concurrently, the effectiveness of radiological and systemic therapies used for the downstaging of hepatocellular carcinoma are increasing. It is now more frequently observed that candidates for liver transplantation have an excellent response to downstaging, even if the baseline stage was well beyond the transplantable tumour. Downstaged patients have a higher risk of dropout from the waiting list and post-transplant recurrence if not transplanted in a short time. Since an increasing number of downstaged patients affects the waitlist dynamics, the definition of upper limits of downstaging is becoming a crucial issue. In this narrative review, we summarise current evidence on the downstaging of hepatocellular carcinoma for liver transplantation, including downstaging of patients with macrovascular invasion or extrahepatic metastasis at presentation and employment of the new systemic treatments for hepatocellular carcinoma. In Europe and the United States, approximately 1100 and 1800 liver transplantations, respectively, are performed every year for hepatocellular carcinoma (HCC), compared with an annual incidence of 65,000 and 39,000 new cases, respectively. Because of organ shortages, proper patient selection is crucial, especially for those exceeding the Milan criteria. Downstaging is the reduction of the HCC burden to meet the eligibility criteria for liver transplantation. Many techniques can be used in downstaging, including ablation, chemoembolisation, radioembolisation and systemic treatments, with a reported success rate of 60–70%. In recent years, an increasing number of patient responders to downstaging procedures has been included in the waitlist, generally with a comparable five-year post-transplant survival but with a higher probability of dropout than HCC patients within the Milan criteria. While the Milan criteria are generally accepted as the endpoint of downstaging, the upper limits of tumour burden for downstaging HCC for liver transplantation are controversial. Very challenging situations involve HCC patients with large nodules, macrovascular invasion or even extrahepatic metastasis at baseline who respond to increasingly more effective downstaging procedures and who aspire to be placed on the waitlist for transplantation. This narrative review analyses the most important evidence available on cohorts subjected to "extended" downstaging, including HCC patients over the up-to-seven criteria and over the University of California San Francisco downstaging criteria. We also address surrogate markers of biological aggressiveness, such as alpha-fetoprotein and the response stability to locoregional treatments, which are very useful in selecting responders to downstaging procedures for waitlisting inclusion. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.